Bayer (BAYN) Given a €105.00 Price Target by Cfra Analysts
A number of other equities research analysts have also recently commented on BAYN. Berenberg Bank set a €124.00 ($153.09) target price on Bayer and gave the company a neutral rating in a research report on Friday, November 3rd. UBS Group set a €125.00 ($154.32) target price on Bayer and gave the company a buy rating in a research report on Monday, November 6th. Barclays set a €105.00 ($129.63) target price on Bayer and gave the company a sell rating in a research report on Monday, November 6th. Goldman Sachs Group set a €125.00 ($154.32) target price on Bayer and gave the company a buy rating in a research report on Tuesday, November 7th. Finally, Jefferies Group set a €137.00 ($169.14) price objective on Bayer and gave the stock a buy rating in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of €119.64 ($147.70).
Shares of Bayer (FRA BAYN) opened at €92.27 ($113.91) on Friday. Bayer has a 12-month low of €91.58 ($113.06) and a 12-month high of €123.82 ($152.86). The company has a market capitalization of $75,580.00 and a PE ratio of 24.80.
COPYRIGHT VIOLATION NOTICE: “Bayer (BAYN) Given a €105.00 Price Target by Cfra Analysts” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/05/bayer-bayn-given-a-105-00-price-target-by-cfra-analysts.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.